Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors

Background Atezolizumab is an engineered immunoglobulin monoclonal antibody that targets the programmed death-1/programmed death-ligand 1 pathway. Methods In this phase I dose-finding study, we assessed the safety, feasibility, pharmacokinetics (PK), and exploratory anti-tumor activity of atezolizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizugaki, Hidenori, Yamamoto, Noboru, Murakami, Haruyasu, Kenmotsu, Hirotsugu, Fujiwara, Yutaka, Ishida, Yoshimasa, Kawakami, Tomohisa, Takahashi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007272/
https://www.ncbi.nlm.nih.gov/pubmed/27363843
http://dx.doi.org/10.1007/s10637-016-0371-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007272/
https://www.ncbi.nlm.nih.gov/pubmed/27363843
http://dx.doi.org/10.1007/s10637-016-0371-6

Ejemplares similares